Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
4 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer.
Clin Cancer Res. 2024 May 1;30(9):1889-1905. doi: 10.1158/1078-0432.CCR-23-2975.
Clin Cancer Res. 2024.
PMID: 38381406
Free PMC article.
CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective.
Zhou FH, Downton T, Freelander A, Hurwitz J, Caldon CE, Lim E.
Zhou FH, et al. Among authors: freelander a.
Front Cell Dev Biol. 2023 Mar 22;11:1148792. doi: 10.3389/fcell.2023.1148792. eCollection 2023.
Front Cell Dev Biol. 2023.
PMID: 37035239
Free PMC article.
Review.
Item in Clipboard
Type 1 Nuclear Receptor Activity in Breast Cancer: Translating Preclinical Insights to the Clinic.
Kumar S, Freelander A, Lim E.
Kumar S, et al. Among authors: freelander a.
Cancers (Basel). 2021 Oct 3;13(19):4972. doi: 10.3390/cancers13194972.
Cancers (Basel). 2021.
PMID: 34638457
Free PMC article.
Review.
Item in Clipboard
Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer.
Freelander A, Brown LJ, Parker A, Segara D, Portman N, Lau B, Lim E.
Freelander A, et al.
Genes (Basel). 2021 Feb 17;12(2):285. doi: 10.3390/genes12020285.
Genes (Basel). 2021.
PMID: 33671468
Free PMC article.
Review.
Item in Clipboard
Cite
Cite